A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
PD-1 and CTLA-4 are checkpoint inhibitors of the immune response in cancer, making them the target molecules for the development of therapeutic antibodies. US2019161548 patent describes a bispecific antibody capable of specifically binding to PD-1 and CTLA-4 that induced the proliferation and activation of CD8+ cells, as well as the expression of induclble co-stimulator in CD4+ T cells. Clinical trials to evaluate safety, dose-limiting toxicities and maximum tolerated/administered dose are still in the patient recruitment phase, but it will be of great interest to the scientific and medical community to know if the first bispecific anti-PD-1/CLTA-4 antibody, exceeds expectations and exceeds action of the combination of nivolumab and epilimumab in the treatment of cancer.
A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry.
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
The high statistics of cancer cases and mortalities throughout the world signify the urgent need for an advanced technology to target tumor cells. Nanotechnology has emerged as one such revolutionary platform to specifically target cancerous tissues and to enhance the efficacy for various anticancer drugs. This report is a snapshot of the patents in chemotherapy from January 2010 to May 2020 involving nanoparticles, novel methods developed for their synthesis and their impact as efficient drug-delivery vehicles.
Sigma-1 receptors (S1Rs) are strongly correlated to neuropathic pain (NP), since their inactivation may decrease allodynia or dysesthesia, promoting analgesic effects. In the recent patent landscape, S1R antagonists endowed with nanomolar S1Rs affinity emerged as potent antinociceptive agents. So far, three patented compounds have been proposed for counteracting NP. Particularly PV-752 and AV1066, disclosed by the University of Pavia (Italy) and Anavex, respectively, showed good analgesic activity in preclinical studies. Moreover, E-52862 developed by Esteve (Spain) has been proved to be effective, both in preclinical and Phase II clinical trials, against several symptoms of NP. These patents ascertain S1R antagonists as potential drugs, alone or in combination with other analgesic drugs, for managing NP in humans.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：